BridgeMD
Evaluation of the real-life efficacy, safety, and immunogenicity of chikungunya vaccination in populations at risk of severe or complicated disease: an ambispective study in La Réunion
EU CTIS ID: 2025-521307-43-00
What this study is testing
To measure the vaccine effectiveness at 6 months (EV) of the chikungunya vaccine on the occurrence of confirmed chikungunya (PCR+ or IgM+ in a participant not previously immunized during the epidemic phase in vulnerable populations.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- For both studies, Signature of informed consent form
- For both studies, Eligible for anti-chikungunya vaccination according to HAS recommendations
- For boths studies, Beneficiary of social security coverage
- For both studies, Agreeing to participate in the study - Adults (≥18 years and under 65)
- For the Retrospective study, adults 18 years and above already vaccinated
- For the Prospective study, adults aged 18-64
You likely can't join if
- Pregnant women
- Vaccine contraindication for patients undergoing medical treatment (e.g. following hematological cancer or solid tumor, administration of chemotherapy, congenital immunodeficiency or long-term immunosuppressive therapy, or severely immunosuppressed HIV-infected patients)
- Persons under guardianship, curatorship or safeguard of justice
- Anyone who has received immunoglobulin or a blood or plasma transfusion 3 months prior to vaccine administration.
- Not beneficiary of Social Security Coverage
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.